Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with ¹²⁵I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts

REFERENCES

• Maraveyas A, Epenetos A. Targeted immunotherapy. Acta Oncol 1993; 32: 741–6.
   PubMed Web of Science ®Google Scholar
• Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403–6.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol 1996; 41: 1915–31.
   PubMed Web of Science ®Google Scholar
• Molthoff CFM, Pinedo HM, Schliiper HMM, Boven E. Influence of dose and schedule on the therapeutic efficacy of 'I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. Int .1- Cancer 1992; 50: 474–80.
   PubMedGoogle Scholar
• Syrigos KN, Epenetos AA. Radioimmunotherapy of ovarian cancer. Hybridoma 1995; 14: 121–3.
   PubMedGoogle Scholar
• Crippa F, Bolis G, Seregni E, et al. Single-dose intraperi-toneal radioimmunotherapy with the murine monoclonal anti-body 1-131 M0v18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 1995; 31A: 686–90.
   PubMed Web of Science ®Google Scholar
• Nustad K, Bast JR RC, O'Brien TJ, etal. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 Workshop. Tumor Biol 1996; 17: 196–219.
   Google Scholar
• Nap M, Vitali A, Nustad K, et al. Immunohistochemical characterization of 22 monoclonal antibodies against the CA 125 antigen: 2nd report from the ISOBM TD-1 workshop. Tumor Biol 1996; 17: 325–31.
   PubMedGoogle Scholar
• Boerman OC, van Niekerk CC, Makkink K, Hanselaar TGJM, Kenemans P, Poels LG. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int .1- Gyn Path 1991; 10: 15–25.
   PubMed Web of Science ®Google Scholar
• Crippa F, Buraggi GL, Di-Re E, etal. Radioimmunoscintigra-phy of ovarian cancer with the M0v18 monoclonal antibody. Eur J Cancer 1991; 27: 724–9.
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. Acta Radiol 1990; 374 (Suppl): 141–5.
   Google Scholar
• Hagan PL, Halpern SE, Dillman RO, et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986; 27: 422–7.
   PubMedGoogle Scholar
• Chiou RK. The impact of tumor size on the efficacy of monoclonal antibody-targeted radiotherapy: studies using a nude mouse model with human renal cell carcinoma xenografts. J Urol 1991; 146: 232–7.
   PubMedGoogle Scholar
• Miotti S, Canevari S, Me'nard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int .1-Cancer 1987; 39: 297–303.
   Google Scholar
• Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991; 51: 5329–38.
   PubMed Web of Science ®Google Scholar
• Lindegren S, Skarnemark G, Jacobsson L, Karlsson B. Chlo-ramine-T in high-specific-activity radioiodination of antibodies using N0-succinimidy1-03-(trimethylstannyl)benzoate as an in-termediate. Nucl Med Biol 1998; 25: 659–65.
   PubMedGoogle Scholar
• Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77–89.
   Google Scholar
• Haisma HJ, Moseley KR, Battaile AI, Griffiths TC, Zurawski VR, Knapp RC. Biodistribution, pharmacokinetics and imag-ing of 131I-labelled OC 125 in ovarian cancer. Int J Cancer 1988; Suppl 2: 109–13.
   Google Scholar
• Muto MG, Finkler NJ, Kassis Al, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC 125. Gynecol Oncol 1992; 45: 265–72.
   PubMed Web of Science ®Google Scholar
• Schneider-Galicke E, Humm JL, Lau CC, Macklis RM, Knapp RC. Analysis of cytotoxicity of 1311-labelled 0C125 F(ab')2 on human epithelial ovarian cancer cell lines. Radiother Oncol 1992; 23: 150–9.
   Google Scholar
• Manetta A, Sataswaroop PG, Hamilton T, Ozolos R, Mortel R. Therapeutic effect of radiolabeled antibody on human ovarian cancer xenografts in nude mice. Gynecol Oncol 1989; 32: 368–70.
   Google Scholar
• Mantovani L, Me'nard S, Mezzanzanica D, Miotti S, Pupa SM, Colnaghi MI. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. Br J Cancer 1990; 62 (Suppl X): 15–7.
   Google Scholar
• Miotti S, Alberti S, Facheris P, et al. Membrane association and shedding of the GPI-anchored Ca-M0v18 antigen in human ovary carcinoma cells. Int J Cancer 1992; 51: 499–505.
   PubMed Web of Science ®Google Scholar
• Boerman OC, Tibben JG, Massuger LFAG, Claessens RAMJ, Corstens FHM. Tumour targeting of the anti-ovarian car-cinoma X anti-CD3/TCR bispecific monoclonal antibody OC/ TR and its parenteral MOv18 antibody in experimental ovarian cancer. Anticancer Res 1995; 15: 2169–74.
   Google Scholar
• Molthoff CFM, Pinedo HM, Schliiper HMM, Nijman HW, Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies 0C125, OV-TL3, and 139H as IgG and F(a1:02 fragments in experimental ovarian cancer. Br J Cancer 1992; 65: 677–83.
   Google Scholar
• Kievit E, Pinedo HM, Schliiper HMM, Haisma HJ, Boven E. Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br J Cancer 1996; 73: 457–64.
   Google Scholar
• Molthoff CFM, Pinedo HM, Schliiper MM, Boven E. Pharma-cokinetics and biodistribution of a new anti-episialin mono-clonal antibody 139H2 in ovarian cancer-bearing nude mice. Cancer Immunol Immunother 1991; 34: 191–7.
   PubMedGoogle Scholar
• Garg PK, Gerald Jr EA, Bigner DD, Zalutsky MR. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. Appl Radiat Isot Int J Radiat Appl Instrum Part A 1989; 6: 485–90.
   Google Scholar
• Zalutsky MR, Narula SN. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstanny1)-benzoate intermediate. Cancer Res 1988; 48: 1446–50.
   PubMedGoogle Scholar
• Zalutsky MR, Noska MA, Colapinto V, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N. succinimi-dyl 3-(tri-n-butylstannyl)benzoate. Cancer Res 1989; 49: 5543–9.
   Google Scholar